Scotia Capital Inc. Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Scotia Capital Inc. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,749 shares of the biopharmaceutical company's stock after buying an additional 14,125 shares during the quarter. Scotia Capital Inc.'s holdings in Gilead Sciences were worth $15,033,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GILD. XTX Topco Ltd acquired a new position in Gilead Sciences during the 3rd quarter worth $581,000. Coldstream Capital Management Inc. boosted its position in shares of Gilead Sciences by 9.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 22,882 shares of the biopharmaceutical company's stock valued at $1,932,000 after purchasing an additional 2,043 shares during the period. TD Private Client Wealth LLC increased its position in Gilead Sciences by 10.6% during the third quarter. TD Private Client Wealth LLC now owns 57,509 shares of the biopharmaceutical company's stock worth $4,822,000 after buying an additional 5,497 shares during the period. Rehmann Capital Advisory Group boosted its stake in Gilead Sciences by 3.6% during the 3rd quarter. Rehmann Capital Advisory Group now owns 9,626 shares of the biopharmaceutical company's stock worth $807,000 after purchasing an additional 333 shares during the period. Finally, Westside Investment Management Inc. raised its stake in Gilead Sciences by 3.5% during the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock valued at $2,249,000 after acquiring an additional 917 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Gilead Sciences Trading Down 1.1 %

NASDAQ:GILD traded down $1.13 on Tuesday, reaching $105.37. 3,343,203 shares of the stock traded hands, compared to its average volume of 7,480,585. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company's 50 day moving average is $108.48 and its 200-day moving average is $97.05. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market capitalization of $131.20 billion, a price-to-earnings ratio of 284.78, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is presently 854.05%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on GILD shares. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. BMO Capital Markets increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Piper Sandler increased their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Oppenheimer boosted their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company lifted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last three months. Company insiders own 0.16% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.